AbbVie (ABBV) Announces SKYRIZI Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults

Press/Media

Period17 Jun 2022 → 18 Jun 2022

Media coverage

2

Media coverage